VolitionRx (NYSE:VNRX) Coverage Initiated by Analysts at StockNews.com

StockNews.com started coverage on shares of VolitionRx (NYSE:VNRX) in a research report released on Saturday morning. The brokerage issued a sell rating on the stock.

Separately, Cantor Fitzgerald restated an overweight rating and set a $2.50 price target on shares of VolitionRx in a research note on Wednesday, March 27th.

VolitionRx Trading Down 7.6 %

Shares of VNRX stock opened at $0.72 on Friday. VolitionRx has a 12 month low of $0.55 and a 12 month high of $2.07. The company has a market cap of $59.09 million, a P/E ratio of -1.53 and a beta of 1.26. The firm has a fifty day moving average price of $0.83 and a 200 day moving average price of $0.85.

VolitionRx (NYSE:VNRX) last announced its quarterly earnings results on Monday, March 25th. The company reported ($0.11) EPS for the quarter. The business had revenue of $0.24 million for the quarter, compared to the consensus estimate of $0.50 million. On average, equities analysts forecast that VolitionRx will post -0.4 EPS for the current year.

Institutional Trading of VolitionRx

A hedge fund recently bought a new stake in VolitionRx stock. Silverberg Bernstein Capital Management LLC bought a new position in shares of VolitionRx Limited (NYSE:VNRX) in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor bought 147,038 shares of the company’s stock, valued at approximately $105,000. Silverberg Bernstein Capital Management LLC owned approximately 0.19% of VolitionRx at the end of the most recent quarter. Institutional investors own 8.09% of the company’s stock.

About VolitionRx

VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose and monitor a range of cancers, and sepsis and COVID-19 in the United States and internationally. The company offers Nu.Q Vet, a cancer screening test for dogs and other animals; Nu.Q Nets for monitoring the immune system; Nu.Q Cancer for monitoring disease progression, response to treatment and minimal residual disease; Capture-PCR, an isolating and capturing circulating tumor derived DNA from plasma samples for early cancer detection; and Nu.Q Discover, a solution to profiling nucleosomes.